Abdul Hakim - La Farsa del 11-M (2010)

Introduccion - Destrucción de los Trenes y Explosivos


Personajes Clave, la Furgoneta y la Mochila


Detenciones, Sentencia y Traslado de Explosivos


"Suicidas" en Leganés y Skoda Fabia


La Manipulación de los Medios



Madrid 11-M, 911 días después (2008)

* La pista atlantista / Segunda parte - By Mathieu Miquel

* Todos están mintiendo (2006) / El ejercicio del terror (2006) / La masacre seguirá impune (2007)

* NATO's Hidden Terrorism - Daniele Ganser's interview by Silvia Cattori (2007)

ITV - What's in your Mouth? (2009)

What's in your Mouth?



New Zealand TV





Smoking Teeth = Poison Gas

Stan Tenen - Squaring The Circle (1999)

* Live at The 3220 Gallery, San Francisco (US)

Cori Brackett - Sweet Misery, A Poisoned World (2004)

Subtitulado



Trailer



Metal Filings in Your Cereal

* Aspartame Side Effects / Other Sweeteners

Pfizer - History

About

- 2000: Merged with Warner-Lambert for $90 billion, 3th major M&A in the last 20 years (-2009).
- 2003: Merged with Pharmacia for $59,515 million, 8th major M&A in the 2000s.
- 2009: Merged with Wyeth.
- Revenue: $50 billion in 2009; $48.3 billion in 2008; $48.4 billion in 2007.
- Adjusted Income: $14.2 billion in 2009; $16.4 billion in 2008; $15.1 billion in 2007.
- Net Income: $8.6 billion in 2009; $8.1 billion in 2008.
- Research & Development: $5.1 billion in 2002; $7.1 billion in 2003; $7.5 billion in 2004; $8.1 billion in 2007; $7.5 billion in 2008; $7.7 billion in 2009.

Sanofi-Aventis - Business

About

- Synthélabo: Created in 1970 and purchased in 1973 by L'Oréal (World's cosmetic leader).
- Sanofi Group: Merger in 1973 of a number of cosmetic, health care, and animal nutrition firms into a corporate subsidiary of the French state-owned Elf Aquitaine oil company (Total).
- Sanofi Bio-industries: Biotechnological center of all Elf Aquitaine's activities.
- Merial = Merger of Merck & Co. Inc. (MSD AgVet) and Sanofi-Aventis (Rhone Mérieux) in 1997.
- Sanofi-Synthélabo = Merger of Sanofi and Synthélabo in 1999.
- Hoechst Marion Roussel = Merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow.
- Aventis = Merger of Rhône-Poulenc S.A. and Hoechst Marion Roussel in 1999.
- Aventis CropScience = Merger of AgrEvo and Rhône-Poulenc Agro in 2000.
- 2004: Sanofi-Synthélabo acquires Aventis by friendly bid of €54.5 billion.
- 2009: Merck sells its 50% of Merial for $4 billion in cash.
- 2010: Equally-owned Joint Venture with Merck by combining Merial (entreprise value fixed at $8 billion) with Intervet/Schering-Plough (entreprise value fixed at $8.5 billion), leading to true-up payment of $250 million to Merck to establish a 50/50 joint venture, and an additional $750 million.
- Full member of the European Federation of Pharmaceutical Industries and Associations.

Merck - Business & Products

About

- Merial = Merger of Merck & Co. Inc. (MSD AgVet) and Sanofi-Aventis (Rhone Mérieux) in 1997. In 2009, Merck sells its 50% to Sanofi-Aventis for $4 billion in cash.
- 2009: Merger of Merck & Co. Inc. (68%) and Schering-Plough (32%) for 41.1 billion dollar deal by 56% stock and 44% cash financed with $9.8 billion from existing cash balances and $8.5 billion from committed financing provided by J.P. Morgan.
- 2010: Equally-owned Joint Venture with Sanofi-Aventis by combining Merial (entreprise value fixed at $8 billion) with Intervet/Schering-Plough (entreprise value fixed at $8.5 billion), leading to true-up payment of $250 million to Merck to establish a 50/50 joint venture, and an additional $750 million.
- Supports the United Nations Global Compact.
- Component of the Dow Jones Industrial Average.
- Member of The Corporate Council on Africa.
- Corporate member of the Council on Foreign Relations.

Groupe Grimaud - Vivalis

About

- Virus manufacturing: Production of a large amount of viral vectors and viruses for the manufacture of viral vaccines, such as poxviruses (vaccinia, MVA, fowl pox...), influenza viruses (human, avian and swine strains), adenoviruses (Celo virus...), reoviruses, birnaviruses (Gumboro virus), etc.
- Protein manufacturing: Production of preclinical and clinical lots of recombinant proteins in animals cell lines, including EB66 cells and CHO cells, in cGMP facility at bioreactor scale.
- Development and commercialization of the EBx technology to manufacture viral vaccines (the vaccine market was worth $8.7 billions in 2005 and $10 billions in 2006), and therapeutic proteins and monoclonal antibodies (the protein market was worth $76 billions in 2006).
- Revenue: €7.5 million in 2009; €8.9 million in 2008; €3.2 million in 2007.
- Cash: €42.5 million in 2010; €23.6 million in 2009; €22.7 million in 2008; €25 million in 2007; €1.8 million in 2006.
- R&D Expenses: €9.8 million in 2008; €8.2 million in 2008; €5.5 million in 2007; €4 million in 2006.
- Patents/Licenses: 180/28 in 2009; 116/24 in 2008; 74/22 in 2007; 54/16 in 2006.

Merck - Schering-Plough

About

- Schering-Plough = Merger of Schering Corporation and Plough Inc. in 1971.
- 2009: Merger of Merck & Co. Inc. (68%) and Schering-Plough (32%). 41.1 billion dollar deal by 56% stock and 44% cash financed with $9.8 billion from existing cash balances and $8.5 billion from committed financing provided by J.P. Morgan.
- Following the entry of the United States into World War II in 1941, U.S. President Franklin Delano Roosevelt ordered Schering AG's U.S. assets be seized, becoming the Schering Corporation. Placed under a government administratorship until 1952, when it was released and its assets sold to the private sector.
- Business operations: More than 140 countries.
- Net Sales: $20.8 billion in 2008 ; $15.2 billion in 2007 ; $12.5 billion in 2006 ; $10.7 billion in 2005.

Sanofi-Aventis - Sanofi Pasteur

About

- Revenue: €2,861 million in 2008 (+9.6% over 2007).
- Net sales: €2,533 millions in 2006 (+22.7% over 2005).
- Sales Growth in 2008: Pediatric Vaccines (+21.9%).
- Sales of Menactra, meningitis vaccine, in 2007: 415 million euros (+87%). In 2008/2009, production capacities should reach 8 to 10 million doses and 20 million by 2010.
- Vaccines Production Doses: >1.6 billion in 2007 ; >1 billion in 2006.
- More than €1 million invested every day in R&D.
- Nearly €1.5 billion invested in 5 years in production capacity.

Groupe Grimaud - Business

About

- 2nd largest multi-species poultry genetics group supplying customers in more than 100 countries from European, U.S., Brazilian and Asian facilities.
- Groupe Grimaud supports the United Nations Global Compact.

Monsanto - History

About

- 2002: The Monsanto Company is spun off from Pharmacia as a separate company.
- 2003: Pfizer acquires Pharmacia.
- Pharmacia Corporation = Merger of Pharmacia & Upjohn Inc. and Monsanto in 2000. Monsanto, agricultural chemical division. Searle, pharmaceutical division.
- Pharmacia & Upjohn Inc. = Merger of Pharmacia AB and The Upjohn Company in 1995. Global headquarters relocated from UK to US in 1998.
- Member of CropLife International.
- Member of The Corporate Council on Africa.